Abdulla Alzibdeh: Tumor-Directed SBRT May Enhance Outcomes in LA-NSCLC on Durvalumab
Abdulla Alzibdeh, Resident Physician at King Hussein Cancer Foundation and Center, shared on LinkedIn:
“ESTRO 2025 Highlight – HypoRT + Durvalumab in LA-NSCLC
Multicenter retrospective study from France evaluated adding tumor SBRT to standard PACIFIC regimen in unresectable stage II–III NSCLC (n=209; SBRT arm: 10%).
Design: All patients received mediastinal normofractionated radiotherapy (NFRT; ≥60 Gy) + platinum CT + ≥1 cycle durvalumab. SBRT arm had <10 fx ≥5 Gy to primary tumor. PSM (1:4) done by age, sex, PS, smoking, T/N stage.
Results:
• SBRT improved PFS (not reached vs 22.3 mo; HR=0.46, p=0.047)
• OS trend favoring SBRT (NR vs 45 mo; HR=0.53, p=0.18)
• Post-NFRT SBRT had stronger PFS signal (p=0.056)
• No ↑ in grade 3–5 toxicity
Takeaway: Tumor-directed SBRT may enhance outcomes in selected LA-NSCLC patients on durvalumab. Role of timing and dose-fx needs more study.”
More posts featuring Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023